57-64-7

57-64-7 structure

Name: Physostigmine salicylate
Chemical Name: Eserine Salicylate
CAS Number: 57-64-7
Molecular Formula: C₂₂H₂₇N₃O₅
Molecular Weight: 413.46700
Catalog: Pharmaceutical intermediate Heterocyclic compound Pyridine compound Cyanopyridine
Create Date: 2018-07-16 15:55:10
Modify Date: 2026-07-06 12:16:28
Physostigmine salicylate (Eserine salicylate) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine salicylate crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine salicylate can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine salicylate is also an antidote for anticholinergic poisoning[1][2][3][4].

Name	Eserine Salicylate
Synonyms	(3aS,8-1,3a,8-triMethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl MethylcbaMate 2-hydroxybenzoate Physostigmine salicylate CRS PHYSOSTIGMINE SALICYLATE INJECTION PHYSOSTIGMINESALICYLATE EINECS -8 Physostigminsalicylat Physostigmine Salicylate, 10 mM in DMSO inhibit,Eserine,antidote,Physostigmine,blood-brain,Physostigmine Salicylate,Alzheimer's,Cholinesterase (ChE),Inhibitor,brier salicylicacid,compd.withphysostigmine(1:1) Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcbamate (ester), (3aS-cis)-, mono(2-hydroxybenzoate) (salt) ESERINE SALICYLATE Eserine salicylate salt >= (N) ESERINE MONOSALICYLATE CCRIS Isopto Eserine Physostigmine-d3 salicylate physostigmine,salicylate(1:1) PHYSOSTIGMINE SALICYLATE //BP Physostigmine salicylate (Eserine salicylate) Benzoic acid, 2-hydroxy-, compd. with (3aS,8-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl methylcbamate (1:1) (9CI) ESERINE SALICYLATE(RG) Benzoicacid,2-hydroxy-,mpd,with(3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indo-ylmethylcbamateester(1:1) Benzoic acid, 2-hydroxy-, compd. with (3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl methylcbamate (1:1) tl-1380 Benzoic acid, 2-hydroxy-, compd. with (3aS,8-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo2,3-bindol-5-yl methylcbamate (1:1) ()-Physostigmine (salicylate) EINECS 200-343-8 MFCD00135659 Salicylic acid, compd. with physostigmine (1:1) (8CI) PHYSOSTIGMINE SALICYLATE SALT physostolsalicylate [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate,2-hydroxybenzoic acid trimethylpyrrolo[2,3-b]indol-5-ylmethylcbamate(1:1) physostigmine,[salicylate(1:1)] 2-hydroxy-,compd.with(3as-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-benzoicaci Physostigmine salicylate (6CI) Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcbamate (ester), (3aS,8)-, mono(2-hydroxybenzoate) (salt) (9CI) Physostigmine Salicylate Physostigmine monosalicylate Physostigmine, monosalicylate (8CI) ESERINE SALICYLATE SALT

Description	Physostigmine salicylate (Eserine salicylate) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine salicylate crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine salicylate can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine salicylate is also an antidote for anticholinergic poisoning[1][2][3][4].
Related Catalog	Research Areas >> Neurological Disease Signaling Pathways >> Neuronal Signaling >> AChE
In Vivo	Physostigmine salicylate (Eserine salicylate; 0.03-0.3 mg/kg; s.c.; daily for 6 weeks) improves deficits in contextual and cued memory in Tg(+) mice[2]. Physostigmine salicylate (IV; 0.1, 0.2 mg/kg) delays time to emergence from isoflurane anesthesia at doses ≥0.2 mg/kg in male Sprague-Dawley rats[4]. Animal Model: Heterozygous transgenic mice (Tg(+) mice)[2] Dosage: 0.03, 0.1, and 0.3 mg/kg Administration: SC; daily for 6 weeks Result: Tended to normalize the contextual memory deficit in Tg(+) animals so that they became more similar to Tg(-) animals.
References	[1]. Haase U, et al. Pharmakotherapie--physostigmin post OP [Pharmacotherapy--physostigmine administered post-operatively]. Anasthesiol Intensivmed Notfallmed Schmerzther. 2007;42(3):188‐189. [2]. Dong H, et al, Bertchume A, Vallera D, Csernansky JG. Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology (Berl). 2005;181(1):145‐152. [3]. Frascogna N. Physostigmine: is there a role for this antidote in pediatric poisonings?. Curr Opin Pediatr. 2007;19(2):201‐205. [4]. Jonathan D Kenny, et al. Physostigmine and Methylphenidate Induce Distinct Arousal States During Isoflurane General Anesthesia in Rats. Anesth Analg. 2016 Nov;123(5):1210-1219.

Boiling Point	393.5ºC at 760 mmHg
Melting Point	181-183 °C
Molecular Formula	C₂₂H₂₇N₃O₅
Molecular Weight	413.46700
Flash Point	191.8ºC
Exact Mass	413.19500
PSA	102.34000
LogP	3.25810
Storage condition	2-8°C

CHEMICAL IDENTIFICATION

RTECS NUMBER :: TJ2450000

CAS REGISTRY NUMBER :: 57-64-7

LAST UPDATED :: 199706

DATA ITEMS CITED :: 15

MOLECULAR FORMULA :: C15-H21-N3-O2.C7-H6-O3

MOLECULAR WEIGHT :: 413.52

WISWESSER LINE NOTATION :: T B556 EN GNTT&J B1 E1 G1 KOVM1 &QR BVO

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 14 ug/kg

TOXIC EFFECTS :: Cardiac - arrhythmias (including changes in conduction) Gastrointestinal - nausea or vomiting

REFERENCE :: JCLPDE Journal of Clinical Psychiatry. (Physicians Postgraduate Press, Inc., POB 240008, Memphis, TN 38124) V.39- 1978- Volume(issue)/page/year: 46,446,1985

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 2 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 25,569,1973

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1280 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DCTODJ Drug and Chemical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.1- 1977/78- Volume(issue)/page/year: 7,507,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 2500 ug/kg

TOXIC EFFECTS :: Behavioral - tremor Behavioral - convulsions or effect on seizure threshold

REFERENCE :: AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 81,276,1950

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 640 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 28,227,1974

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 800 ug/kg

TOXIC EFFECTS :: Behavioral - tremor Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - cyanosis

REFERENCE :: JPPMAB Journal of Pharmacy and Pharmacology. (Pharmaceutical Soc. of Great Britain, 1 Lambeth High St., London SEI 7JN, UK) V.1- 1949- Volume(issue)/page/year: 34,603,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 310 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959- Volume(issue)/page/year: 20,474,1971

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 1200 ug/kg

TOXIC EFFECTS :: Autonomic Nervous System - other (direct) parasympathomimetic Behavioral - coma Lungs, Thorax, or Respiration - respiratory stimulation

REFERENCE :: NTIS** National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information. Volume(issue)/page/year: PB158-508

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Mammal - cat

DOSE/DURATION :: 800 ug/kg

TOXIC EFFECTS :: Autonomic Nervous System - other (direct) parasympathomimetic Behavioral - coma Lungs, Thorax, or Respiration - respiratory stimulation

REFERENCE :: NTIS** National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information. Volume(issue)/page/year: PB158-508

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 2 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: AEXPBL Archiv fuer Experimentelle Pathologie und Pharmakologie. (Leipzig, Ger. Dem. Rep.) V.1-109, 1873-1925. For publisher information, see NSAPCC. Volume(issue)/page/year: 53,313,1905

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 1570 ug/kg

TOXIC EFFECTS :: Behavioral - tremor

REFERENCE :: AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 81,276,1950 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 200 ug/kg

SEX/DURATION :: male 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles)

REFERENCE :: PHBHA4 Physiology and Behavior. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1- 1966- Volume(issue)/page/year: 4,677,1969 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 80481 No. of Facilities: 68 (estimated) No. of Industries: 1 No. of Occupations: 6 No. of Employees: 2770 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 80481 No. of Facilities: 54 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 1828 (estimated) No. of Female Employees: 1354 (estimated)

Symbol	GHS06
Signal Word	Danger
Hazard Statements	H300-H330
Precautionary Statements	P260-P264-P284-P301 + P310-P310
Personal Protective Equipment	Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
Hazard Codes	T+: Very toxic;
Risk Phrases	R26/28
Safety Phrases	S25-S45
RIDADR	UN 1544 6.1/PG 1
WGK Germany	3
RTECS	TJ2450000
Packaging Group	II
Hazard Class	6.1(a)
HS Code	2933990090

HS Code	2933990090
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

228118-00-1	841288-19-5
634882-68-1	26095-04-5
793727-94-3	1190002-89-1
874950-25-1	775293-38-4
879048-78-9	303126-05-8